Diabetes type 2

BRIGHT publication

The RESTORE-G Real World Evidence Study

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

Switching from other basal insulins to Toujeo® (Insulin Glargine)

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Highlights ATTD 2024

Diabetes en ramadan: ORION studie

Ondanks de mogelijkheid voor een medische uitzondering, bleek uit een groot wereldwijd onderzoek dat vier van de tien moslims met diabetes type 1 en acht van de tien moslims met diabetes type 2 meer dan vijftien dagen vasten tijdens de ramadan.²